Table 1 Baseline characteristics at admission, interventions, and mortality of patients admitted to ICU with SARS-Cov 2 pneumonia. Differences between patients according to each wave
Characteristics | All Patients | Wave 1 (N = 51) | Wave 2 (N = 133) | Wave 3 (N = 191) | Wave 4 (N = 62) | P-value |
|---|---|---|---|---|---|---|
Patients | ||||||
Age, years, median (Q1;Q3) | 65 (55;72) | 65 (56;72) | 68 (60;75) | 66 (56;72) | 57 (45;65) | < 0.001 |
Male, n (%) | 309 (71%) | 36 (71%) | 107 (81%) | 124 (65%) | 42 (68%) | 0.0241 |
Charlson score, median (Q1;Q3) | 1 (0;2) | 1 (0;3) | 1 (0;3) | 1 (0;3) | 0 (0;1) | 0.0085 |
Chronic kidney disease, n(%) | 39 (9%) | 10 (20%) | 9 (7%) | 18 (9%) | 2 (3%) | 0.0129 |
BMI, kg/m2, median (Q1;Q3) | 28 (25;32) | 26 (23;29) | 28 (25;33) | 28 (26;31) | 29 (27;33) | 0,00109 |
ICU admission | ||||||
SAPS II, median (Q1;Q3) | 32 (22;44) | 41 (31;49.5) | 40 (29;51) | 30 (21;40) | 24 (17;30.5) | < 0.001 |
SOFA, median (Q1;Q3) | 4 (2;7) | 7 (4.5;9) | 4 (2;7) | 3 (2;7) | 3 (2;6) | < 0.001 |
PaO2/FiO2 ratio, median (Q1;Q3) | 147 (106;182) | 146 (110;164) | 160 (113;200) | 137 (100;174) | 150 (116;165) | 0,09 |
D-dimer, ng/mL, median (Q1;Q3) | 990 (594;1867) | 1138 (787;1774) | 865 (492;1626) | 1041 (681;1963) | 899 (527;1480) | 0.0246 |
Lactates, mmol/L, median (Q1;Q3) | 1,3 (1,0;1,7) | 1,3 (1,0;1,7) | 1,3 (1,0;1,7) | 1,3 (1,0;1,7) | 1,3 (1,0;1,5) | 0,618 |
CRP, mg/L, median (Q1;Q3) | 141 (84;216) | 238 (152;303) | 160 (93;228) | 123 (77;199) | 120 (73;178) | 8,35.10–8 |
Lymphocytes, 109/L, median (Q1;Q3) | 0,7 (0,5;0,92) | 0,68 (0,5;0,98) | 0,69 (0,46;0,86) | 0,71 (0,51;0,92) | 0,77 (0,59;1) | 0,119 |
ICU stay | ||||||
MV, n (%) | 282 (65%) | 46 (90%) | 87 (65%) | 114 (60%) | 35 (57%) | < 0.001 |
duration (n = 280), days, median (Q1;Q3) | 9 (5;20) | 6 (3;11) | 9 (5;19) | 12 (6;22) | 11 (7;28) | < 0.001 |
Vasopressors a, n (%) | 48 (11%) | 15 (30%) | 4 (8%) | 4 (8%) | 5 (10%) | < 0.001 |
Dexamethasone, n (%) | 357 (82%) | 0 (0%) | 133 (98%) | 167 (87%) | 60 (97%) | < 0.001 |
AKI, n (%) | 135 (31%) | 26 (51%) | 49 (37%) | 49 (26%) | 12 (19%) | < 0.001 |
RRT, n (%) | 54 (12%) | 16 (31%) | 9 (7%) | 24 (13%) | 5 (8%) | < 0.001 |
ECMO, n (%) | 8 (2%) | 2 (4%) | 1 (1%) | 4 (2%) | 1 (2%) | 0,534 |
VAP, n (%) | 170 (39%) | 13 (26%) | 55 (41%) | 76 (40%) | 26 (42%) | 0,795 |
CAPA, n (%) | 22 (5%) | 3 (6%) | 8 (6%) | 7 (4%) | 4 (7%) | 0,717 |
ICU LOS, days, median (Q1;Q3) | 8 (4;15) | 8 (4;14) | 8 (4;15) | 8 (4;16) | 7 (4;15) | 0,945 |
Hospital LOS, days, median (Q1;Q3) | 20 (12;33) | 18 (10;39) | 18 (11;29) | 22 (14;34) | 19 (12;35) | 0,19 |
Mortality, n (%) | ||||||
In ICU | 53 (12%) | 13 (26%) | 13 (10%) | 20 (11%) | 7 (11%) | 0.0209 |
In-hospital | 68 (16%) | 17 (33%) | 15 (12%) | 28 (15%) | 8 (14%) | 0.0037 |